InterMune, Inc.
(NASDAQ : ITMN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
1.20%302.971.4%$587.98m
AMGNAmgen, Inc.
0.43%234.411.3%$520.14m
GILDGilead Sciences, Inc.
2.19%67.381.0%$371.60m
REGNRegeneron Pharmaceuticals, Inc.
1.14%372.522.6%$303.90m
VRTXVertex Pharmaceuticals, Inc.
0.26%223.661.9%$268.83m
ILMNIllumina, Inc.
2.38%327.413.5%$238.63m
ARWRArrowhead Pharmaceuticals, Inc.
1.99%66.8312.0%$190.93m
EXASEXACT Sciences Corp.
3.52%86.5524.0%$184.71m
ALXNAlexion Pharmaceuticals, Inc.
6.08%113.952.0%$180.47m
CLVSClovis Oncology, Inc.
9.82%9.7314.7%$178.04m
SRPTSarepta Therapeutics, Inc.
-0.54%109.3714.6%$148.03m
AAgilent Technologies, Inc.
0.77%82.161.6%$141.58m
BMRNBioMarin Pharmaceutical, Inc.
0.66%80.614.3%$130.96m
SGENSeattle Genetics, Inc.
0.33%117.556.1%$128.31m
NBIXNeurocrine Biosciences, Inc.
-0.35%116.085.0%$127.12m

Company Profile

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.